Article Text

PDF

Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception
  1. Nathaniel Henry1,
  2. Max Schlueter2,
  3. Julia Lowin3,
  4. Ingrid Lekander4,
  5. Anna Filonenko5,
  6. James Trussell6,
  7. Finn Egil Skjeldestad7
  1. 1Senior Consultant, Real World Evidence Solutions, IMS Health, London, UK
  2. 2Consultant, Real World Evidence Solutions, IMS Health, London, UK
  3. 3Director, Real World Evidence Solutions, IMS Health, London, UK
  4. 4Health Economist, Bayer AB, Solna, Sweden
  5. 5Project Leader, Global Market Access, Bayer Pharma AG, Berlin, Germany
  6. 6Professor of Economics and Public Affairs; Faculty Associate, Office of Population Research, Princeton University, Princeton, NJ, USA
  7. 7Professor of Reproductive Epidemiology, Gynaecology and Obstetrics, Department of Clinical Medicine, University of Tromsø, Tromsø, Norway
  1. Correspondence to Mr Max Schlueter, IMS Health, 210 Pentonville Road, London N1 9JY, UK; mschlueter{at}uk.imshealth.com

Abstract

Objectives The objective of this study was to quantify the cost burden of unintended pregnancies (UPs) in Norway, and to estimate the proportion of costs due to imperfect contraceptive adherence. Potential cost savings that could arise from increased uptake of long-acting reversible contraception (LARC) were also investigated.

Methods An economic model was constructed to estimate the total number of UPs and associated costs in women aged 15–24 years. Adherence-related UP was estimated using ‘perfect use’ and ‘typical use’ contraceptive failure rates. Potential savings from increased use of LARC were projected by comparing current costs to projected costs following a 5% increase in LARC uptake.

Results Total costs from UP in women aged 15–24 years were estimated to be 164 million Norwegian Kroner (NOK), of which 81.7% were projected to be due to imperfect contraceptive adherence. A 5% increase in LARC uptake was estimated to generate cost savings of NOK 7.2 million in this group.

Conclusions The cost of UP in Norway is substantial, with a large proportion of this cost arising from imperfect contraceptive adherence. Increased LARC uptake may reduce the UP incidence and generate cost savings for both the health care payer and contraceptive user.

  • long-acting reversible contraception
  • health economics

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Highlights from this issue
    British Medical Journal Publishing Group